Environmental factors such as air pollution, allergens, and occupational hazards play a significant role in the development and exacerbation of respiratory diseases. Increasing urbanization, industrialization, and exposure to pollutants contribute to the rise in respiratory conditions worldwide.
According to data reported by Eurostat (European Commission), respiratory disorders accounted for around 6.7% of all the deaths in European Union in 2020.
Additionally, indoor air pollution from sources such as tobacco smoke, cooking fumes, mold, and indoor allergens can exacerbate respiratory conditions and increase the risk of respiratory infections. Poor ventilation and inadequate housing conditions further contribute to indoor air quality-related respiratory issues.
Overall, the increase in the prevalence of respiratory diseases is a multifaceted issue influenced by demographic, environmental, lifestyle, and healthcare-related factors. As respiratory conditions become more prevalent globally, the demand for effective cough remedies is expected to continue growing, driving market expansion in the coming years.
Authors:
Mariam Faizullabhoy, Gauri Wani
Frequently Asked Questions (FAQ) :
The market size of cough remedies reached USD 9.2 billion in 2023 and is set to witness 5.6% CAGR from 2024 to 2032, owing to growing prevalence of respiratory conditions and increasing air pollution levels.
The oral syrups segment accounted for 45.4% of the market share in 2023, due to personal preferences or ease of use.
North America market size was USD 3.4 billion in 2023 and is anticipated to grow at 5.1% CAGR between 2024
AstraZeneca plc, Bayer AG, GSK plc, Johnson & Johnson, Novartis AG, Pfizer Inc., Prestige Consumer Healthcare, Procter & Gamble, Reckitt Benckiser Group plc and Sun Pharmaceutical Industries Ltd.